Cover Image
Market Research Report

Generics in Russia

Published by MarketLine Product code 353042
Published Content info 33 Pages
Delivery time: 1-2 business days
Price
Back to Top
Generics in Russia
Published: January 4, 2016 Content info: 33 Pages
Description

Generics in Russia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Russia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Russian generics market is expected to generate total revenues of $10.0bn in 2015, representing a compound annual growth rate (CAGR) of 15.4% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 79.9% of total pharma volume in 2015.
  • The Russian pharmaceuticals market is large and dominated by "branded" generic products and imports. The system is largely undeveloped, as the majority of drugs are bought by patients themselves, who are greatly influenced by advertising. The country has around 500 pharmaceutical companies but many are small. The companies' size and the investment in marketing and sales rather than creation means that mainly older drugs are produced.

Features

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Russia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Russia
  • Leading company profiles reveal details of key generics market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Russia generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the Russia economy

Key Questions Answered

  • What was the size of the Russia generics market by value in 2015?
  • What will be the size of the Russia generics market in 2020?
  • What factors are affecting the strength of competition in the Russia generics market?
  • How has the market performed over the last five years?
  • How large is Russia's generics market in relation to its regional counterparts?
Table of Contents
Product Code: OHME4919

Table of Contents

Executive Summary

  • Market value
  • Market value forecast
  • Market volume
  • Market volume forecast
  • Geography segmentation
  • Market rivalry

Market Overview

  • Market definition
  • Market analysis

Market Data

  • Market value
  • Market volume

Market Segmentation

  • Geography segmentation

Market Outlook

  • Market value forecast
  • Market volume forecast

Five Forces Analysis

  • Summary
  • Buyer power
  • Supplier power
  • New entrants
  • Threat of substitutes
  • Degree of rivalry

Leading Companies

  • Abbott Laboratories
  • Krka, d. d., Novo mesto
  • Teva Pharmaceutical Industries Limited

Macroeconomic Indicators

  • Country Data

Methodology

  • Industry associations
  • Related MarketLine research

Appendix

  • About MarketLine

List of Tables

  • Table 1: Russia generics market value: $ billion, 2011-15(e)
  • Table 2: Russia generics market volume: % of total pharma volume, 2011-15(e)
  • Table 3: Russia generics market geography segmentation: $ billion, 2015(e)
  • Table 4: Russia generics market value forecast: $ billion, 2015-20
  • Table 5: Russia generics market volume forecast: % of total pharma volume, 2015-20
  • Table 6: Abbott Laboratories: key facts
  • Table 7: Abbott Laboratories: key financials ($)
  • Table 8: Abbott Laboratories: key financial ratios
  • Table 9: Krka, d. d., Novo mesto: key facts
  • Table 10: Krka, d. d., Novo mesto: key financials ($)
  • Table 11: Krka, d. d., Novo mesto: key financials (€)
  • Table 12: Krka, d. d., Novo mesto: key financial ratios
  • Table 13: Teva Pharmaceutical Industries Limited: key facts
  • Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
  • Table 16: Russia size of population (million), 2011-15
  • Table 17: Russia gdp (constant 2005 prices, $ billion), 2011-15
  • Table 18: Russia gdp (current prices, $ billion), 2011-15
  • Table 19: Russia inflation, 2011-15
  • Table 20: Russia consumer price index (absolute), 2011-15
  • Table 21: Russia exchange rate, 2011-15

List of Figures

  • Figure 1: Russia generics market value: $ billion, 2011-15(e)
  • Figure 2: Russia generics market volume: % of total pharma volume, 2011-15(e)
  • Figure 3: Russia generics market geography segmentation: % share, by value, 2015(e)
  • Figure 4: Russia generics market value forecast: $ billion, 2015-20
  • Figure 5: Russia generics market volume forecast: % of total pharma volume, 2015-20
  • Figure 6: Forces driving competition in the generics market in Russia, 2015
  • Figure 7: Drivers of buyer power in the generics market in Russia, 2015
  • Figure 8: Drivers of supplier power in the generics market in Russia, 2015
  • Figure 9: Factors influencing the likelihood of new entrants in the generics market in Russia, 2015
  • Figure 10: Factors influencing the threat of substitutes in the generics market in Russia, 2015
  • Figure 11: Drivers of degree of rivalry in the generics market in Russia, 2015
  • Figure 12: Abbott Laboratories: revenues & profitability
  • Figure 13: Abbott Laboratories: assets & liabilities
  • Figure 14: Krka, d. d., Novo mesto: revenues & profitability
  • Figure 15: Krka, d. d., Novo mesto: assets & liabilities
  • Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Back to Top